Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice

NCT02109250 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT02109250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02109250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
Lead sponsor
Genzyme, a Sanofi Company
Phase
Observational
Overall status
Completed
Start date
April 30, 2014
Completion date
June 30, 2015
Enrollment
10 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic medullary thyroid cancer